Real-world data: come possono aiutare a migliorare la qualità dell’assistenza
- PMID: 36627865
- PMCID: PMC9616184
- DOI: 10.33393/grhta.2021.2286
Real-world data: come possono aiutare a migliorare la qualità dell’assistenza
Abstract
The current COVID pandemic crisis made it even clearer that the solutions to several questions that public health must face require the access to good quality data. Several issues of the value and potential of health data and the current critical issues that hinder access are discussed in this paper. In particular, the paper (i) focuses on “real-world data” definition; (ii) proposes a review of the real-world data availability in our country; (iii) discusses its potential, with particular focus on the possibility of improving knowledge on the quality of care provided by the health system; (iv) emphasizes that the availability of data alone is not sufficient to increase our knowledge, underlining the need that innovative analysis methods (e.g., artificial intelligence techniques) must be framed in the paradigm of clinical research; and (v) addresses some ethical issues related to their use. The proposal is to realize an alliance between organizations interested in promoting research aimed at collecting scientifically solid evidence to support the clinical governance of public health.
Conflict of interest statement
Conflict of interest: GA, GA, GB, PC, EC, FD, CLV, MM, WM, AM, AP, WR, FRdM, FS and VT have nothing to declare. AA received personal fees and/or grants from BMS, MSD, Roche, Astra Zeneca, Eli-Lilly, Takeda e Bayer. GWC received personal fees and/or grants from A. Menarini, Alk-Abelló, Allergy Therapeutics, AstraZeneca-Medimmune, Boehringer Ingelheim, Chiesi Farmaceutici, Genentech, Guidotti-Malesci, Glaxo Smith Kline, Hal Allergy, Merck Sharp & Dome, Mundipharma, Novartis, Orion, Sanofi-Aventis, Sanofi Genzyme/Regeneron, Stallergenes-Greer, Uriach Pharma, Teva, Valeas, ViforPharma. GC received personal fees and/or grants from the European Community, AIFA, Ministeri dell’Università e Ricerca (MIUR), Novartis, GSK, Roche, AMGEN, BMS, Roche. APM received personal fees and/or grants from Bayer, Fresenius, Novartis. GM received personal fees and/or grants from Astra Zeneca, Boehringer Ingelheim, Daiichi Sankyo, Medtronic, Menarini, Merck, Novartis, Recordati, Sandoz, Sanofi, Servier. AM received personal fees and/or grants from Ventana, Pierre Fabre, Verily, Abbvie, AstraZeneca, Verseau Therapeutics, Compungen, Myeloid Therapeutics, Third Rock Venture, Imcheck Therapeutics, Ellipses, Novartis, Roche, Macrophage Pharma, Bioveloclta, Merck, Principia, BMS, Johnson & Johnson. Declares commercial interest in Cedarlane Laboratories Ltd, HyCult Biotechnology, eBioscience, Biolegend, ABCAM PIc, Novus Biologicals, Enzo Life, Affymetrix. AR received personal fees and/or grants from Amgen, Pfizer, Sanofi, Novartis, Kite-Gilead, Celgene-BMS, Jazz, Omeros.
References
LinkOut - more resources
Full Text Sources